Marshall Wace, LLP Fulcrum Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $63.3 Billion
- Q1 2024
A detailed history of Marshall Wace, LLP transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 225,573 shares of FULC stock, worth $1.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
225,573
Previous 505,102
55.34%
Holding current value
$1.4 Million
Previous $3.41 Million
37.55%
% of portfolio
0.0%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding FULC
# of Institutions
135Shares Held
43.7MCall Options Held
3.12MPut Options Held
128K-
Rtw Investments, LP New York, NY5.85MShares$36.2 Million0.89% of portfolio
-
Cowen And Company, LLC3.71MShares$23 Million1.18% of portfolio
-
Suvretta Capital Management, LLC New York, NY2.85MShares$17.6 Million1.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.54MShares$15.7 Million0.0% of portfolio
-
Trv Gp Iv, LLC Boston, MA2.34MShares$14.5 Million10.72% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $322M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...